Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in ...

Chili's® Grill & Bar is shifting into high gear for the 2025 NASCAR season with the launch of its new 'Ride the Dente'tm campaign. The campaign is part of a multi-race partnership extension with Spire ...

Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

While Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...

The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors.

The stock's fall snapped a three-day winning streak.

Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a 50 day moving average price of $714.37 and a two-hundred day moving average price of ...